Barosi, G
Tefferi, A
Besses, C
Birgegard, G
Cervantes, F
Finazzi, G
Gisslinger, H
Griesshammer, M
Harrison, C
Hehlmann, R
Hermouet, S
Kiladjian, J-J
Kröger, N
Mesa, R
Mc Mullin, M F
Pardanani, A
Passamonti, F
Samuelsson, J
Vannucchi, A M
Reiter, A
Silver, R T
Verstovsek, S
Tognoni, G
Barbui, T
Article History
Received: 27 June 2014
Revised: 25 July 2014
Accepted: 28 July 2014
First Online: 25 August 2014
Competing interests
: SH, CH, JJK, RM, AR, JS and MFMM received honoraria and had consulting role in Novartis; JJK, CH had a speakers’ bureau in Novartis; JJK, RH and CB received research funds from Novartis; G Birgegard had a consulting/advisory role in Shire; RM received research funding from Incyte, Gilead, Celgene, Genentech and NS Pharma; and SV received research funding from: Incyte Corporation, Astrazeneca, Lilly Oncology, Roche, Geron, NS Pharma, Bristol Myers Squibb, Novartis, Celgene, Infinity Pharmaceuticals, YM Biosciences, Seattle Genetics, Promedior, and Cell Therapeutics Inc. The remaining authors declare no conflict of interest.